Acute ST Elevation Myocardial Infarction
Conditions
Brief summary
The research question to be addressed is Does a 2.5 - 5 minute systemic intravenous injection of sodium nitrite administered immediately before opening of the infarct related artery result in significant reduction of ischaemia reperfusion injury in patients with first acute ST elevation myocardial infarction (MI)?
Detailed description
There are estimated to be 125,000 acute myocardial infarctions (heart attacks) in the UK every year. Although substantial progress has been made in reducing the infarct size by prompt opening of the infarct related artery (with thrombolytic therapy or percutaneous coronary intervention (PCI)), effective therapy to further reduce the infarct size would substantially reduce the risk of the patient subsequently developing heart failure. There is a growing body of evidence from studies in animals that the use of nitrites may help in reducing the infarct size, although this has not been tested in man. In this phase 2/3 study, the investigators propose to investigate the effect of sodium nitrite injection on infarct size. Eligible patients will be males aged 18 and over and females aged 55 and over, presenting within 12 hours of the onset of chest pain, who are suitable for treatment with percutaneous coronary intervention. Those who give verbal agreement to take part will receive a 2.5-5 minute injection of sodium nitrite (or placebo) immediately prior to the blocked artery being opened with percutaneous coronary intervention.
Interventions
DRUGsodium nitrite
sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
OTHERPlacebo
sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
Sponsors
NHS Grampian
Medical Research Council
St George's Healthcare NHS Trust
Brighton and Sussex University Hospitals NHS Trust
Imperial College London
University of Birmingham
University of Aberdeen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Men aged ≥18 years, women aged ≥55 years, and women \<55years who are sterilised, or have had a hysterectomy or have effective contraception and thus where there is no possibility of them being pregnant; presenting within 12 hours of the onset of chest pain who have ST segment elevation of more than 1mm elevation in limb leads or 2mm elevation in two contiguous chest leads or new left bundle branch block (LBBB) and for whom the clinical decision has been made to treat with primary PCI will be eligible for enrolment. Occlusion of the culprit related artery (TIMI grade 0 or TIMI grade 1) will also be required for inclusion. Eligible patients will be of North European descent.
Exclusion criteria
* Historical or ECG evidence of previous myocardial infarction * Patients with prior coronary artery bypass grafting (CABG) * Prior revascularization procedure where this procedure (PCI) was performed in the same territory as the current infarct * Known or suspected pregnancy * Contra-indications to MRI * Patients with cardiac arrest or cardiogenic shock * Patients with left main coronary occlusion * Patients with known moderate to severe renal failure (estimated GFR \< 30mls/min), or liver failure * Patients with prior thrombolysis for this event * Patients with such Left Main disease which after PCI of their culprit lesion (culprit lesions may be located in the LAD or LCx or RCA) are likely to require CABG within the time course of the study period (6 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infarct size corrected for area at risk (using ESA) | 6-8 days post injection |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction and end systolic volume index | 6-8 days and 6 months post injection |
| Plasma creatine kinase | 72 hours post injection |
| Troponin I | 72 hours post injection |
| Infarct size corrected for area at risk | 6 months |
| Infarct size corrected for area at risk (using T2) | 6-8 days |
Countries
United Kingdom
Outcome results
None listed